PL3723808T3 - Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn - Google Patents
Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydynInfo
- Publication number
- PL3723808T3 PL3723808T3 PL18830165T PL18830165T PL3723808T3 PL 3723808 T3 PL3723808 T3 PL 3723808T3 PL 18830165 T PL18830165 T PL 18830165T PL 18830165 T PL18830165 T PL 18830165T PL 3723808 T3 PL3723808 T3 PL 3723808T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazolo
- pyridines
- administration
- combination treatments
- treatments
- Prior art date
Links
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical class C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 title 1
- 238000011284 combination treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700711 | 2017-12-14 | ||
| EP18830165.9A EP3723808B1 (en) | 2017-12-14 | 2018-12-12 | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
| PCT/EP2018/084434 WO2019115567A1 (en) | 2017-12-14 | 2018-12-12 | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3723808T3 true PL3723808T3 (pl) | 2022-01-24 |
Family
ID=64959284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18830165T PL3723808T3 (pl) | 2017-12-14 | 2018-12-12 | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11851425B2 (pl) |
| EP (1) | EP3723808B1 (pl) |
| JP (1) | JP2021506780A (pl) |
| KR (1) | KR20200099155A (pl) |
| CN (1) | CN111526890B (pl) |
| AR (1) | AR113926A1 (pl) |
| AU (1) | AU2018385454C1 (pl) |
| BR (1) | BR112019016839A2 (pl) |
| CA (1) | CA3085202A1 (pl) |
| CL (1) | CL2020001550A1 (pl) |
| CO (1) | CO2020007130A2 (pl) |
| CY (1) | CY1124850T1 (pl) |
| ES (1) | ES2900561T3 (pl) |
| HR (1) | HRP20211785T1 (pl) |
| HU (1) | HUE056882T2 (pl) |
| IL (1) | IL275293B2 (pl) |
| LT (1) | LT3723808T (pl) |
| MX (1) | MX2020006228A (pl) |
| PL (1) | PL3723808T3 (pl) |
| PT (1) | PT3723808T (pl) |
| RS (1) | RS62552B1 (pl) |
| RU (1) | RU2020119080A (pl) |
| SG (1) | SG11202005333TA (pl) |
| SI (1) | SI3723808T1 (pl) |
| SM (1) | SMT202100657T1 (pl) |
| WO (1) | WO2019115567A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN111465410B (zh) | 2017-12-14 | 2022-10-25 | H.隆德贝克有限公司 | 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗 |
| JP7194738B2 (ja) * | 2017-12-20 | 2022-12-22 | ハー・ルンドベック・アクチエゼルスカベット | ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| WO2005028480A2 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| ATE415400T1 (de) | 2004-07-05 | 2008-12-15 | Astellas Pharma Inc | Pyrazolopyridinderivate |
| US7652035B2 (en) | 2004-10-19 | 2010-01-26 | Neurocrine Bioscience, Inc. | CRF receptor antagonists and methods relating thereto |
| US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| RU2402549C3 (ru) | 2005-04-14 | 2022-03-10 | Оцука Фармасьютикал Ко., Лтд. | Пиперазин-замещенные бензотиофены для лечения психических расстройств |
| SI1963280T1 (sl) | 2005-12-22 | 2016-02-29 | Newron Pharmaceuticals S.P.A. | 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US9006258B2 (en) * | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| EP2124944B1 (en) | 2007-03-14 | 2012-02-15 | Ranbaxy Laboratories Limited | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| CN102223799A (zh) | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| WO2011153135A1 (en) * | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| LT3042917T (lt) | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| SG194216A1 (en) | 2011-04-21 | 2013-11-29 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| WO2013142307A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics | Carbamate compounds and of making and using same |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| UA116023C2 (uk) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| EA031132B1 (ru) | 2014-02-19 | 2018-11-30 | Х. Лундбекк А/С | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| US20170273985A1 (en) | 2014-09-18 | 2017-09-28 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| TW201629064A (zh) * | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| TW201639851A (zh) | 2015-03-16 | 2016-11-16 | 大日本住友製藥股份有限公司 | 雙環咪唑衍生物 |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| PE20181015A1 (es) | 2015-08-12 | 2018-06-26 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 |
| US20180344680A1 (en) | 2015-12-08 | 2018-12-06 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers |
| DE112015007181T5 (de) | 2015-12-09 | 2018-08-23 | Ford Global Technologies, Llc | Warnung für zurückgelassenes Mobilgerät |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN111465410B (zh) | 2017-12-14 | 2022-10-25 | H.隆德贝克有限公司 | 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗 |
| JP7194738B2 (ja) | 2017-12-20 | 2022-12-22 | ハー・ルンドベック・アクチエゼルスカベット | ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
-
2018
- 2018-12-11 AR ARP180103616A patent/AR113926A1/es unknown
- 2018-12-12 AU AU2018385454A patent/AU2018385454C1/en not_active Expired - Fee Related
- 2018-12-12 KR KR1020207019017A patent/KR20200099155A/ko not_active Ceased
- 2018-12-12 EP EP18830165.9A patent/EP3723808B1/en active Active
- 2018-12-12 US US16/772,612 patent/US11851425B2/en active Active
- 2018-12-12 ES ES18830165T patent/ES2900561T3/es active Active
- 2018-12-12 BR BR112019016839A patent/BR112019016839A2/pt unknown
- 2018-12-12 JP JP2020531991A patent/JP2021506780A/ja active Pending
- 2018-12-12 SI SI201830454T patent/SI3723808T1/sl unknown
- 2018-12-12 PL PL18830165T patent/PL3723808T3/pl unknown
- 2018-12-12 CA CA3085202A patent/CA3085202A1/en active Pending
- 2018-12-12 SG SG11202005333TA patent/SG11202005333TA/en unknown
- 2018-12-12 CN CN201880079959.5A patent/CN111526890B/zh active Active
- 2018-12-12 WO PCT/EP2018/084434 patent/WO2019115567A1/en not_active Ceased
- 2018-12-12 SM SM20210657T patent/SMT202100657T1/it unknown
- 2018-12-12 RU RU2020119080A patent/RU2020119080A/ru unknown
- 2018-12-12 HR HRP20211785TT patent/HRP20211785T1/hr unknown
- 2018-12-12 RS RS20211373A patent/RS62552B1/sr unknown
- 2018-12-12 HU HUE18830165A patent/HUE056882T2/hu unknown
- 2018-12-12 PT PT188301659T patent/PT3723808T/pt unknown
- 2018-12-12 MX MX2020006228A patent/MX2020006228A/es unknown
- 2018-12-12 LT LTEPPCT/EP2018/084434T patent/LT3723808T/lt unknown
-
2020
- 2020-06-10 CL CL2020001550A patent/CL2020001550A1/es unknown
- 2020-06-11 IL IL275293A patent/IL275293B2/en unknown
- 2020-06-11 CO CONC2020/0007130A patent/CO2020007130A2/es unknown
-
2021
- 2021-11-24 CY CY20211101019T patent/CY1124850T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200099155A (ko) | 2020-08-21 |
| SMT202100657T1 (it) | 2022-01-10 |
| MX2020006228A (es) | 2022-09-27 |
| PT3723808T (pt) | 2021-11-25 |
| AR113926A1 (es) | 2020-07-01 |
| IL275293B2 (en) | 2023-07-01 |
| SI3723808T1 (sl) | 2022-01-31 |
| AU2018385454C1 (en) | 2024-06-27 |
| HUE056882T2 (hu) | 2022-03-28 |
| LT3723808T (lt) | 2021-11-25 |
| ES2900561T3 (es) | 2022-03-17 |
| CO2020007130A2 (es) | 2020-06-19 |
| IL275293A (en) | 2020-07-30 |
| BR112019016839A2 (pt) | 2020-04-07 |
| HRP20211785T1 (hr) | 2022-02-18 |
| CA3085202A1 (en) | 2019-06-20 |
| IL275293B1 (en) | 2023-03-01 |
| CN111526890A (zh) | 2020-08-11 |
| AU2018385454A1 (en) | 2020-07-02 |
| AU2018385454B2 (en) | 2024-02-29 |
| CY1124850T1 (el) | 2022-11-25 |
| RS62552B1 (sr) | 2021-12-31 |
| RU2020119080A (ru) | 2022-01-14 |
| EP3723808A1 (en) | 2020-10-21 |
| EP3723808B1 (en) | 2021-10-20 |
| WO2019115567A1 (en) | 2019-06-20 |
| CN111526890B (zh) | 2022-10-14 |
| JP2021506780A (ja) | 2021-02-22 |
| CL2020001550A1 (es) | 2020-09-25 |
| US20200385372A1 (en) | 2020-12-10 |
| US11851425B2 (en) | 2023-12-26 |
| SG11202005333TA (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802976B (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| ZA201902562B (en) | Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides | |
| IL255488B (en) | Pyrido[4,3-di]pyrimidine derivative and its pharmaceutically acceptable salt | |
| SG11201907095UA (en) | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
| IL246311A0 (en) | Pyrazolo[5,1-a]pyridine derivatives and methods of using them | |
| ZA201808257B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| IL252578B (en) | History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them | |
| ZA202003514B (en) | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines | |
| IL275293A (en) | Combined treatments that include administration of H1 - pyrazolo[4, 3-B]pyridines | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| PL3597648T3 (pl) | METODA WYTWARZANIA 3,6-DIPODSTAWIONEJ POCHODNEJ IMIDAZO[1, 2-b]PIRYDAZYNY | |
| IL243739A0 (en) | History of 1h-pyrazolo[4,3-b]pyridine and their pharmaceutical preparations for the treatment of proliferative disorders |